Exact Sciences expects to double number of Cologuard tests performed, EndoChoice projects $18.6M in Q4 revenue & more –7 GI/endoscopy company key notes

Here are seven recent news updates on gastroenterology and endoscopy companies.

EndoChoice released its unaudited, preliminary financial results for the fourth quarter and full year of 2015. The scope maker expects to report $18.6 million in total revenue for the fourth quarter, up from $18.3 million in the fourth quarter of 2014.

EndoChoice entered into a distribution agreement with Chindex Medical.

Cologuard, Exact Sciences' stool DNA based colorectal cancer screen test, has new modeling data supporting a three-year testing interval.

More than 100,000 Cologuard tests were completed by the end of 2015, but Exact Sciences expects the number of its stool DNA-based colorectal cancer screening tests completed in 2016 will more than double.

SonarMD, a web-based application designed to allow physicians to monitor Crohn's disease patients' health status between in-person visits, has formed a partnership with Digestive Healthcare Center of New Jersey in Hillsborough Township.

Takeda Pharmaceutical and enGene, a privately held biotechnology company, announced a new strategic alliance. Through the alliance, the company aims to develop and commercialize novel therapies for specialty gastrointestinal diseases using enGene's gene delivery platform, Gene Pill.

VolitionRX, a developer of blood tests that can predict colon cancer, is looking to start selling the blood test system in the United States in the next year.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast